INOVIQ Limited Overview
INOVIQ is a micro-cap Australian biotechnology company built around a proprietary exosome (small extracellular vesicle) isolation platform, EXO-NET®. It has two small commercial revenue lines. The first is EXO-NET research-use exosome capture products, distributed worldwide by Promega Corporation. The second is the hTERT immunocytochemistry test, an adjunct to urine cytology for bladder cancer, sold directly to US laboratories. Total product revenue was only A$0.43m in FY2026. The company's value rests on its pipeline. The lead asset is EXO-OC™, an exosome-miRNA plus CA125 blood test for early ovarian cancer detection, which INOVIQ intends to launch first as a US Laboratory Developed Test (LDT). The second is a preclinical CAR-exosome (CAR-NK-EV) cell-free therapy platform targeting triple-negative breast, lung and ovarian cancers, with first-in-human studies targeted for 2028. It also holds the SubB2M-based neuCA15-3 breast cancer monitoring assay. INOVIQ ended FY2026 with A$9.35m in cash and no material debt. In July 2026 it suffered a significant setback when a 1,200-sample EXO-OC validation study failed on sample quality.
Company's own description (Annual Report FY2026)
The FY2026 Directors' Report defines the group's principal activities as developing and commercialising diagnostics and therapeutics for cancer. It describes a portfolio of commercial exosome isolation products and an adjunct bladder cancer test, clinical-stage diagnostics for breast and ovarian cancers, and a preclinical CAR-exosome therapeutic program for solid tumours. The Review of Operations calls INOVIQ an integrated diagnostics and therapeutics company. Its core technology isolates extracellular vesicles with high specificity and purity, supporting minimally invasive early cancer detection and targeted, cell-free solid tumour treatment. The CEO's report frames the strategy as moving from research tools to diagnostics and therapeutics, aiming at larger global markets with greater clinical impact.
Independent characterisation
In substance, INOVIQ is a pre-commercial, platform-based oncology biotech with a small product revenue "tail." It has three distinct economic engines:
-
Research tools (EXO-NET®, NEURO-NET, customNET). These are bead-based exosome capture reagents sold for research use only (RUO). Revenue comes from product sales to Promega, the exclusive global distribution partner, which resells to academic and government institutes, biopharma companies and clinical laboratories. Promega reported 90 EXO-NET customers by the end of FY2026, up from about 60 in mid-2025. EXO-NET revenue nevertheless fell to A$138,045 in FY2026 from A$253,261 in FY2025, which the company attributes to channel inventory timing.
-
Legacy IVD (hTERT ICC test). This line was inherited from the 2020 acquisition of Sienna Cancer Diagnostics. The test is registered as a Class I IVD in the US and sold directly to pathology laboratories. Revenue has flattened at about A$0.29m a year, and management expects it to stay flat in FY2027 because the market is small and competition is rising.
-
Pipeline (diagnostics and therapeutics). This includes EXO-OC™ (ovarian cancer early detection), neuCA15-3 (breast cancer monitoring, based on SubB2M), and the CAR-exosome platform (EEV-001 for TNBC, EEV-002 for NSCLC and EEV-003 for ovarian cancer). Planned monetisation runs through LDT laboratory partnering in the US for EXO-OC, licensing or partnering for neuCA15-3, and eventual clinical development, likely partnered, for CAR-exosomes.
Revenue model mix (FY2026)
| Revenue type | FY2026 (AUD) | Share of product revenue | Model |
|---|---|---|---|
| hTERT test (product sales, US direct) | 294,002 | 68.0% | Product, direct to labs |
| EXO-NET (product sales to Promega) | 138,045 | 32.0% | Product, distributor model |
| Licensing / royalty income | 0 | 0% | A royalty entitlement on any future BARD1 lung test sales exists under the 2022 settlement; no income recognised |
| Service / subscription | 0 | 0% | Not applicable |
| Total product revenue | 432,047 | 100% | — |
Source: AR FY2026, Review of Operations and Statement of Comprehensive Income. Shares are derived.
Non-operating "other income" (A$2.18m in FY2026) is far larger than product revenue. It consisted mainly of the R&D Tax Incentive refund accrual (A$1.78m) and interest income (A$0.40m).
Value chain position, customers and end-markets
Value chain: INOVIQ sits upstream as an IP owner and reagent and assay developer. It uses distributors (Promega) and is seeking a US CLIA-certified laboratory partner for EXO-OC. Manufacturing of EXO-NET was centralised in its Melbourne laboratory in FY2023, according to the HY2023 report. For CAR-exosomes, the company is selecting a CDMO and sourcing GMP-compliant cells (AR FY2026).
Customer types: academic and government research institutes, biopharma, clinical laboratories and hospitals (EXO-NET); US pathology laboratories (hTERT); and prospectively US reference laboratories, payers and women at high risk of ovarian cancer (EXO-OC).
End-markets: exosome and extracellular vesicle research tools; liquid biopsy and cancer diagnostics (ovarian, breast, bladder); and cell-free oncology therapeutics.
Strategy
Stated strategy (AR FY2026, paraphrased themes)
Mission: to improve patient lives through earlier cancer detection and more effective treatment, built on exosome technologies.
Platform leverage: use one exosome isolation and engineering platform across research tools, diagnostics and therapeutics, so that multiple products share the same underlying technology.
Staged value ladder: move from revenue-generating research tools to higher-value diagnostics (EXO-OC as a US LDT first, then IVD) and therapeutics (CAR-exosomes toward first-in-human studies).
Partner-led commercialisation: Promega for research tools; a US CLIA laboratory for EXO-OC; partners for neuCA15-3.
Capital discipline: concentrate spending on EV diagnostic and therapeutic programs.
FY2027 priorities (AR FY2026, Outlook)
-
Complete EXO-OC™ development and validation in average-risk and high-risk groups.
-
Progress EXO-OC™ toward LDT readiness and US laboratory partnering.
-
Advance CAR-exosome therapeutics toward manufacturing readiness and future clinical development.
-
Maintain disciplined capital allocation across EV diagnostic and therapeutic programs.
-
Deliver milestones that support long-term shareholder value.
For comparison, the FY2026 priorities set in AR FY2025 were: expand EXO-NET and grow revenue; advance EXO-OC toward commercialisation; move CAR-exosomes into in vivo efficacy studies for breast cancer; and execute strategic partnerships. Delivery against these was mixed. In vivo CAR-exosome proof of concept was achieved. EXO-NET revenue fell. EXO-OC validation failed on sample quality. No diagnostic commercialisation partnership was signed.
Strategic initiatives in the last 24 months (October 2024 to October 2026)
| Date | Initiative | Type | Status |
|---|---|---|---|
| 1 Apr 2025 | UQ research collaboration with Prof Carlos Salomon Gallo on ovarian exosomal biomarkers | R&D partnership | Converted to an exclusive licence (Sep 2025) |
| May 2025 | neuCA15-3 peer-reviewed validation (Breast Cancer Research and Treatment) | Clinical evidence | Moving to an automated platform |
| FY2025 to FY2026 | CAR-exosome in vivo program with Peter MacCallum Cancer Centre | R&D collaboration | In vivo TNBC data reported 22 Dec 2025 |
| 26 Sep 2025 | Exclusive worldwide licence from UniQuest for ovarian exosomal biomarkers | IP in-licensing | Executed |
| 13 Oct 2025 | A$9.5m placement plus SPP (A$10.2m total) with Tian An Medicare as cornerstone | Capital / strategic investor | Completed November 2025 |
| Oct to Dec 2025 | Board renewal: Gunzburg returns as Chair | Governance | Completed |
| Jan 2026 | CSO appointment (Dr Rebecca Lim) bringing CDMO and IND experience | Capability build | Completed |
| FY2026 | EXO-OC expanded clinical study (up to 2,000 samples) | Clinical validation | Failed on sample quality (1 Jul 2026); redesign under way |
| May 2026 | EXO-OC PCT patent application | IP | Filed 29 May 2026 |
| FY2027 | CAR-exosome manufacturing readiness (GMP cells, CDMO selection, dual-action CAR-exosomes) | Platform investment | In progress |
| FY2027 | US LDT partner discussions for EXO-OC | Commercial partnering | Active discussions; no agreement announced |
ESG commitments: none published.
Cost programs: no formal cost-reduction program with targets has been announced.
Medium-term targets and guidance
INOVIQ gives no revenue or earnings guidance. Its non-financial milestones are an independent EXO-OC validation study (FY2027), technology transfer to a US CLIA laboratory, and CAR-exosome first-in-human studies targeted for 2028. Management guided hTERT revenue to be flat in FY2027.
Products & Services
Pipeline overview (AR FY2026, Product Portfolio page)
| Program | Category | Indication | Intended use | Stage (FY2026) |
|---|---|---|---|---|
| EXO-NET® | Research tool | Pan-exosome isolation | RUO biomarker discovery and diagnostics development | In market (global via Promega) |
| NEURO-NET | Research tool | Brain-derived exosome isolation | Neurological disease research (validated in Parkinson's disease) | Research tool, evaluations |
| customNET | Research tool | Bespoke exosome capture | Partner-specific applications | Evaluations |
| hTERT ICC test | IVD | Bladder cancer | Adjunct to urine cytology | In market (US Class I IVD) |
| EXO-OC™ LDT | Diagnostic | Ovarian cancer | Early detection, high-risk women | Clinical (validation reset after July 2026) |
| EXO-OC™ IVD | Diagnostic | Ovarian cancer | Screening, average-risk women | Earlier stage; follows the LDT |
| neuCA15-3 | Diagnostic (SubB2M) | Breast cancer | Monitoring | Assay development / clinical validation |
| EEV-001 | Therapeutic (CAR-exosome) | Triple-negative breast cancer | EGFR-targeted CAR-NK-EV therapy | Preclinical (in vitro and in vivo proof of concept) |
| EEV-002 | Therapeutic (CAR-exosome) | Non-small cell lung cancer | CAR-exosome therapy | Preclinical (in vitro) |
| EEV-003 | Therapeutic (CAR-exosome) | Ovarian cancer | CA125- and EGFR-targeted CAR-exosomes | Preclinical (in vitro) |
| EXO-ACE™ | Manufacturing platform | Therapeutic exosomes | Scalable CAR-exosome production | Published proof of concept (JoVE, Oct 2025) |
| BARD1 autoantibody (breast and ovarian) | Diagnostic IP | Breast and ovarian cancer | Legacy program | Under review, de-prioritised (IP retained) |
Product-by-product detail
EXO-NET® pan-exosome capture tool
Description: A proprietary "Molecular NET" capture technology that isolates exosomes from body fluids. The company claims advantages in speed, specificity, purity, yield and scalability over conventional methods such as ultracentrifugation and size-exclusion.
Target customers: EV researchers in academia and government, biopharma biomarker groups, and clinical laboratories and hospitals.
Launch: RUO product commercialised in Australia first, then launched in the US in October 2022. A high-throughput (HT) EXO-NET system was developed with Promega in FY2023. Promega has been the global distribution partner since 2024, placing its first order in June 2024 and its third order during FY2026.
Customer base: about 60 Promega customers by mid-2025 (Roic.ai summary of company disclosures) and 90 by the end of FY2026 (AR FY2026). Adoption was strongest in Europe, then North America, then Asia-Pacific.
Pricing: Not publicly disclosed.
Revenue: A$138,045 in FY2026, down 45.5%.
Pipeline extension: An EXO-NET/RNA combination product for automated workflows was being developed with Promega, with launch targeted for Q3 FY2026 (Roic.ai summary of company materials). The FY2026 annual report sections reviewed did not confirm the launch.
NEURO-NET
Description: An EXO-NET variant that selectively captures brain-derived (neuronal) exosomes from blood. It was further validated in Parkinson's disease during FY2025 (HY2025 report).
Target customers: Neuroscience and neurodegenerative disease researchers and diagnostic developers.
Status: Research tool under evaluation. Revenue not separately disclosed.
customNET
Description: Bespoke capture formats developed with partners. Multiple evaluations were run in FY2026 across cancer, cardiology and neurology (AR FY2026).
hTERT ICC test
Description: An immunocytochemistry assay that detects human telomerase reverse transcriptase in cytopathology samples. It is used alongside urine cytology to resolve indeterminate results and flag patients at higher bladder cancer risk.
Regulatory: Registered as a Class I IVD medical device in the US.
Channel: Sold directly to US laboratories. The FY2021 quarterly reports referred to a former distributor, StatLab Medical Products.
Revenue: A$294,002 in FY2026, flat. Management expects flat FY2027 revenue because of limited market size and new competing products.
Origin: Acquired with Sienna Cancer Diagnostics in July 2020.
EXO-OC™ ovarian cancer test (lead diagnostic)
Description: A blood test that isolates exosomes with EXO-NET and combines several exosomal miRNA biomarkers with plasma CA125 in an AI/machine-learning algorithm.
Performance history: - 498-sample single-site retrospective study (ASX, 2 June 2025): 100% sensitivity for Stage I/II and 77% for all stages at 99.6% specificity.
-
Optimised algorithm (FY2026): 92.3% sensitivity for Stage I/II and 92.5% for all stages at 98% specificity. The training set had 338 samples and the test set 146 (AR FY2026).
-
Expanded study (up to 2,000 samples planned; first stage about 1,200 samples from five commercial biorepositories). Sample analysis began in April 2026. On 1 July 2026 the study was declared unsuitable for performance evaluation. One provider supplied 616 samples, including 69% of cancer cases, and those samples showed reduced protein and miRNA levels consistent with degradation. Pre-analytical variability was also significant across all providers. The company states these issues were unrelated to the test or EXO-NET. The June 2026 quarterly report put the cost of the study at about A$850k.
Commercial plan: Launch first as a US LDT through a CLIA-certified laboratory partner for high-risk women (BRCA1/2 carriers, Lynch syndrome, strong family history). Develop later as an IVD for average-risk screening.
IP: Provisional patent converted to an International (PCT) application on 29 May 2026. An exclusive worldwide licence to University of Queensland ovarian exosomal biomarkers was obtained from UniQuest on 26 September 2025.
Pricing: Not disclosed.
neuCA15-3 breast cancer monitoring test (SubB2M platform)
Description: Pairs a CA15-3 monoclonal antibody with SubB2M, an engineered protein that binds the tumour-associated glycan Neu5Gc. The aim is to detect tumour-derived CA15-3 more specifically and reduce false positives.
Performance: 81% sensitivity and 93% specificity across all stages, major subtypes and post-treatment monitoring (AR FY2026). Peer-reviewed validation was published in Breast Cancer Research and Treatment in May 2025.
Next steps: Transfer to a bead-based chemiluminescent assay on high-throughput automated platforms, run an in-clinic monitoring study, and secure a commercialisation partner.
CAR-exosome therapeutics (EEV-001, EEV-002, EEV-003)
Description: Cell-free therapy derived from CAR-engineered NK cells. The resulting extracellular vesicles inherit the parent cells' tumour targeting and cytotoxicity. Potential advantages claimed include off-the-shelf manufacture, safety and cost compared with autologous CAR-T.
Data: - FY2025: 88% killing of TNBC and NSCLC cells in vitro (Appendix 4E FY2025).
-
18 September 2025: more than 90% TNBC cell killing within 10 hours in vitro.
-
22 December 2025: in vivo TNBC mouse model showed 61.5% tumour burden reduction with EGFR-CAR-NK-EVs, compared with 24.5% for unmodified NK-EVs. No adverse effects were observed, and targeting was precise.
-
June 2026: ovarian cancer cell lines. CA125-CAR-exosomes killed more than 90% of OVCAR-3 and Caov-3 cells within 48 hours, and EGFR-CAR-exosomes killed more than 80%. Both killed about 50% of aggressive SK-OV-3 cells.
Manufacturing: Proprietary EXO-ACE™ platform (JoVE publication, 1 October 2025). FY2027 work covers GMP cell sourcing, CDMO selection and next-generation dual-action CAR-exosomes.
Timeline: First-in-human studies targeted for 2028.
Collaborator: Peter MacCallum Cancer Centre for in vivo TNBC studies (Roic.ai summary of company disclosures).
BARD1 autoantibody tests (legacy)
- BARD1-Ovarian and BARD1-Breast autoantibody tests were the company's founding programs. The lung test IP was transferred to the founders under the November 2022 settlement, with INOVIQ keeping a royalty. The breast and ovarian IP was retained, but those programs are not prioritised in the current pipeline.
Financial Narrative
Sources: Appendix 4E and Annual Reports FY2022 to FY2026. Balance sheet and cash flow totals for FY2022 to FY2024 are cross-checked against Stockopedia's annual report extracts. All figures are AUD under AASB/IFRS.
Income statement
Revenue CAGR FY2022 to FY2026 was about 11.8% a year, from a very small base. The FY2022 loss is the audited figure. It includes non-cash impairments and replaced the unaudited A$6.5m loss in the August 2022 Appendix 4E (INOVIQ release, 28 September 2022).
Detailed P&L, FY2025 to FY2026 (A$)
Source: AR FY2026, Consolidated Statement of Comprehensive Income (p.32).
Derived EBITDA (analyst calculation, A$ millions). Method: loss before tax, plus amortisation (intangibles and patents), plus depreciation (right-of-use, buildings, plant), plus lease interest, minus interest income. Inputs are from the AR FY2026 expense disclosures.
Expense trend, FY2023 to FY2026 (A$ millions)
Sources: AR FY2024 (p.16), AR FY2025 (p.14), AR FY2026 (p.13). The FY2024 R&D figure is as reported in AR FY2024.
Commentary. The loss profile has stabilised at A$6.5m to A$7.5m a year since FY2024, after a peak in FY2022 caused by impairments. The FY2023 loss was swollen by legal costs: professional and legal fees reached A$2.15m in FY2023, versus A$0.61m in FY2024, mainly from defending the Supreme Court writ. The FY2026 mix is notable. G&A fell 8.4%, helped by a A$87k share-based payments credit after options cancelled on the former Chairman's resignation were reversed. R&D rose 43.5% to A$4.67m, with external contractor spend up to A$2.82m from A$1.69m, reflecting the EXO-OC clinical study and CAR-exosome work. The R&D Tax Incentive refund accrual of A$1.78m effectively funds about 38% of gross R&D spend. Product revenue covers less than 5% of operating expenditure, so the business depends entirely on equity funding and tax refunds.
Balance sheet
Sources: AR FY2026 (p.33) for FY2025 and FY2026; Stockopedia annual report extracts for FY2022 to FY2024. Equity for FY2022 to FY2024 is derived as total assets minus total liabilities.
Detailed FY2025 to FY2026 balance sheet (A$)
Debt and net cash (A$ millions)
Commentary. The balance sheet is clean, with no bank debt apart from a small equipment loan. However, accumulated losses reached A$70.2m against A$87.7m of contributed equity. Intangibles of A$7.7m (hTERT and Molecular NETs, plus patents) make up 41% of net assets and amortise at about A$0.96m a year. An impairment risk exists if the hTERT outlook deteriorates further. The right-of-use asset and lease liability both fell to zero at 30 June 2026. This suggests the Notting Hill lease either expired or moved to a short-term or new arrangement after balance date. The terms are not publicly disclosed in the material reviewed.
Cash flow
Sources: AR FY2026 cash flow statement (p.35) for FY2025 and FY2026; Stockopedia for FY2022 to FY2024.
FY2026 operating detail: product receipts were A$462,942; payments to suppliers and employees A$8,487,366; interest received A$397,388; and the R&D tax refund received A$1,267,738 (relating to FY2025). Financing comprised share issue proceeds of A$10,199,939, less issue costs of A$597,023, lease payments of A$178,653 and equipment loan repayments of A$38,045.
Cash runway (analyst estimate). FY2026 operating burn was A$6.38m including the FY2025 refund. Cash at 30 June 2026 was A$9.35m, with a further A$1.78m FY2026 R&D refund receivable expected in coming months. Assuming a similar spend level, this implies about 14 to 20 months of funding from 30 June 2026, which points to a probable capital need in 2027.
Ratios
ROE and ROA use average equity and average assets (FY2021 equity A$29.04m and total assets A$33.5m, from Stockopedia).
Not meaningful: ROIC, net debt/EBITDA and interest coverage are negative or meaningless because EBIT and EBITDA are negative and the company holds net cash. The cash conversion cycle is not meaningful because inventory (A$38k) and trade receivables tied to product sales are immaterial. Receivables are dominated by the R&D tax refund.
Inflection analysis. The financial trajectory has three phases.
-
FY2021 to FY2022: post-merger integration and impairment. The Sienna acquisition, the BARD1 autoantibody review and impairments drove the FY2022 loss of A$18.2m.
-
FY2023 to FY2025: operating discipline and first EXO-NET revenue. Losses fell to about A$6.5m to A$6.9m, and EXO-NET revenue grew from A$35k to A$253k.
-
FY2026: reinvestment in clinical validation and therapeutics. R&D rose 43%, a A$10.2m raise was completed, but EXO-NET revenue fell back and the flagship validation study failed on sample quality.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Role |
|---|---|---|---|
INOVIQ Limited | Australia | Parent (ASX-listed) | Group holding company; R&D; HQ and laboratory |
Sienna Cancer Diagnostics Ltd | Australia | 100% | Legacy Sienna entity (hTERT, NETs IP; Sienna Cancer Diagnostics® trademark) |
INOVIQ Inc | United States | 100% | US commercial operations (hTERT direct sales; EXO-NET US activity) |
Product Lines
| Product line (AUD) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
hTERT test revenue | 363,209 | 333,255 | 294,314 | 294,002 |
EXO-NET revenue | 34,984 | 201,863 | 253,261 | 138,045 |
Total product revenue | 398,193 | 535,118 | 547,575 | 432,047 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
hTERT YoY growth | 0 | -8.2 | -11.7 | -0.1 |
EXO-NET YoY growth | 0 | 477.0 | 25.5 | -45.5 |
hTERT share of revenue | 91.2 | 62.3 | 53.7 | 68.0 |
EXO-NET share of revenue | 8.8 | 37.7 | 46.3 | 32.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 0.277 | 0.398 | 0.535 | 0.548 | 0.432 |
Revenue growth (%) | -40.9 | 43.9 | 34.4 | 2.3 | -21.1 |
Net loss after tax (AUD Mn) | -18.196 | -8.969 | -6.554 | -6.932 | -7.505 |
Basic EPS (AUD cents) | -20.03 | -9.75 | -7.09 | -6.23 | -5.69 |
Diluted EPS (AUD cents) | -20.03 | -9.75 | -7.09 | -6.23 | -5.69 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Net margin (%) | -6,575 | -2,252 | -1,225 | -1,266 | -1,737 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement (AUD) and Margin Analysis (%)
| Line item (AUD) | FY2025 | FY2026 |
|---|---|---|
Product revenue | 547,575 | 432,047 |
Cost of sales | -120,386 | -76,709 |
Gross profit | 427,189 | 355,338 |
Gross margin (%) | 78.0 | 82.2 |
R&D Tax Incentive refund | 1,267,738 | 1,782,316 |
Interest and miscellaneous income | 411,744 | 399,788 |
General and administration | -5,313,080 | -4,867,071 |
Research and development | -3,254,552 | -4,669,680 |
Sales and marketing | -471,319 | -505,814 |
Total operating expenditure | -9,038,951 | -10,042,565 |
Loss before income tax | -6,932,280 | -7,505,123 |
Income tax | 0 | 0 |
Loss after tax | -6,932,280 | -7,505,123 |
Foreign currency translation (OCI) | -76,684 | 200,014 |
Total comprehensive loss | -7,008,964 | -7,305,109 |
Income Statement
| Metric (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Loss before tax | -6.932 | -7.505 |
Amortisation | 0.980 | 0.960 |
Depreciation | 0.400 | 0.370 |
Lease interest | 0.022 | 0.021 |
Interest income | -0.412 | -0.400 |
EBITDA (derived) | -5.942 | -6.554 |
Key Financials
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
G&A expense (AUD Mn) | 6.833 | 5.159 | 5.313 | 4.867 |
R&D expense (AUD Mn) | 3.224 | 2.700 | 3.255 | 4.670 |
R&D tax incentive income (AUD Mn) | 0.950 | 1.017 | 1.268 | 1.782 |
Amortisation of hTERT and NETs intangibles (AUD Mn) | 0.945 | 0.948 | 0.945 | 0.945 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 15.40 | 7.81 | 9.23 | 6.52 | 9.35 |
Total current assets (AUD Mn) | 17.50 | 9.40 | 10.90 | 8.70 | 11.76 |
Total assets (AUD Mn) | 30.80 | 21.50 | 21.70 | 18.46 | 20.45 |
Total current liabilities (AUD Mn) | 1.80 | 1.52 | 1.53 | 1.51 | 1.26 |
Total liabilities (AUD Mn) | 2.49 | 1.89 | 1.72 | 1.74 | 1.56 |
Total equity (AUD Mn) | 28.31 | 19.61 | 19.98 | 16.71 | 18.89 |
Working capital (AUD Mn) | 15.70 | 7.88 | 9.37 | 7.19 | 10.50 |
Balance Sheet (AUD)
| Line item (AUD) | FY2025 | FY2026 |
|---|---|---|
Cash and cash equivalents | 6,520,923 | 9,353,441 |
Trade and other receivables (mainly R&D refund) | 1,578,781 | 2,022,882 |
Inventories | 46,794 | 37,736 |
Prepayments | 555,840 | 345,241 |
Building improvements, plant and equipment | 953,607 | 974,055 |
Intangible assets | 8,678,789 | 7,718,816 |
Right-of-use assets | 122,484 | 0 |
Total assets | 18,457,218 | 20,452,171 |
Trade and other payables | 880,221 | 761,119 |
Lease liability | 162,253 | 0 |
Equipment loan (current plus non-current) | 213,936 | 289,390 |
Provisions (current plus non-current) | 486,374 | 509,517 |
Total liabilities | 1,742,784 | 1,560,026 |
Net assets | 16,714,434 | 18,892,145 |
Issued capital | 78,049,135 | 87,652,051 |
Accumulated losses | -62,998,968 | -70,196,198 |
Key Financials (FY2025–FY2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
Short-term debt incl. lease (AUD Mn) | 0.200 | 0.060 |
Long-term debt (AUD Mn) | 0.176 | 0.229 |
Total debt incl. lease (AUD Mn) | 0.376 | 0.289 |
Net cash (AUD Mn) | 6.145 | 9.064 |
Goodwill (AUD Mn) | 0 | 0 |
Intangibles (AUD Mn) | 8.679 | 7.719 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -6.06 | -7.02 | -4.32 | -4.66 | -6.38 |
Capex (AUD Mn) | -0.412 | -0.292 | -0.174 | -0.104 | -0.168 |
Free cash flow (AUD Mn) | -6.47 | -7.31 | -4.49 | -4.77 | -6.55 |
Financing cash flow (AUD Mn) | 16.90 | -0.27 | 5.91 | 2.05 | 9.39 |
Net change in cash (AUD Mn) | 10.40 | -7.58 | 1.42 | -2.71 | 2.84 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | -63.4 | -37.4 | -33.1 | -37.8 | -42.2 |
ROA (%) | -56.6 | -34.3 | -30.3 | -34.5 | -38.6 |
Current ratio (x) | 9.72 | 6.18 | 7.12 | 5.75 | 9.37 |
Asset turnover (x) | 0.009 | 0.015 | 0.025 | 0.027 | 0.022 |
Margin Analysis (%)
| Ratio (FY2025 to FY2026) | FY2025 | FY2026 |
|---|---|---|
Debt/equity (%) | 2.3 | 1.5 |
R&D / revenue (%) | 594 | 1,081 |
Gross margin (%) | 78.0 | 82.2 |
Product Lines — hTERT test
| Product line | Primary geography of end-sales | Basis |
|---|---|---|
hTERT test (68% of FY2026 revenue) | United States | Sold directly to US laboratory customers; registered as a US Class I IVD |
EXO-NET (32% of FY2026 revenue) | Invoiced to Promega (US-headquartered). End-customers are mainly in Europe, then North America, then Asia-Pacific. | Promega customer adoption commentary, AR FY2026 |
Geographic Revenue
| Region (AUD) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Americas / Europe / APAC revenue split | 0 | 0 | 0 |
Share Price and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Closing share price (AUD) | 0.39 | 0.85 | 0.56 | 0.37 | 0.545 |
EPS (AUD) | -0.2003 | -0.0975 | -0.0709 | -0.0623 | -0.0569 |
Share Price History
| Date | Price (AUD) | Note |
|---|---|---|
Feb 2021 (as BD1) | 2.86 | Intraday price on the day the founder lawsuit was announced (Stockhead) |
8 Oct 2025 | 0.415 | Last close before the placement |
13 Oct 2025 | 0.35 | Placement price |
23 Jun 2026 | 0.565 (intraday high) | 52-week high, during the run-up before EXO-OC data |
30 Jun 2026 | 0.545 | Last price before the halt |
2 Jul 2026 | 0.27 | After the EXO-OC update |
1 Sep 2026 | 0.18 | Per AR FY2026 |
Latest available | about 0.175 to 0.20 | InvestSMART (quote dates not specified) |
Approximate Change by Period
| Period | Approximate change |
|---|---|
1-year (Oct 2025 to Oct 2026) | about -55% to -58% |
3-year (about A$0.58 to A$0.61 in Oct 2023) | about -70% |
5-year (vs. A$2.86 in early 2021) | more than -90%. |
Calendar 2026 year to date (A$0.39 start) | about -50% |
Valuation Snapshot
| Metric | Value |
|---|---|
Market capitalisation | about A$24.6m |
Net cash (30 Jun 2026) | A$9.06m (cash A$9.35m less debt A$0.29m). Current cash is likely lower after Q1 FY2027 burn. |
Enterprise value | about A$15.6m (based on June 2026 net cash) |
EV/Sales (FY2026) | about 36x |
P/E | Not meaningful (loss-making) |
EV/EBITDA | Not meaningful (EBITDA negative) |
P/B | about 1.3x (book equity A$18.89m) |
P/NTA | about 2.2x (NTA about A$11.17m, or about A$0.08 per share; InvestSMART also shows NTA per share of A$0.08) |
Peer multiples | ASX micro-cap diagnostics peers are mostly loss-making and are typically valued on cash backing and pipeline; comparable EV/Sales multiples are not meaningful. |
Capital Markets
| Item | Status |
|---|---|
Dividend history | No dividends have ever been declared or paid, including FY2025 and FY2026 |
Dividend policy | None (pre-profit biotech) |
Buyback | No on-market buyback in place (AR FY2026) |
Capital raised (recent) | FY2022 about A$16.9m net; FY2024 A$7m placement plus SPP (A$2.4m received July 2024); FY2026 A$10.2m (placement plus SPP), A$9.6m net of costs |
Options outstanding | 6,075,000 unlisted IOP options (1 Sep 2026); 9,753,913 listed options expired 8 Jul 2026 |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile | Equipment loan only: A$60,390 current and A$229,000 non-current at 30 June 2026. No bonds or bank facilities. |
Analyst Conclusions
Management guidance
-
No financial guidance has been issued.
-
hTERT revenue is expected to be flat in FY2027.
-
The FY2027 operational focus is: independent EXO-OC validation using controlled samples (single provider, nested prospective study or real-world study); LDT readiness and US CLIA laboratory partnering; CAR-exosome manufacturing readiness (GMP cells, CDMO); and first-in-human studies targeted for 2028.
Consensus expectations
No consensus revenue or earnings forecasts are publicly available. A one-analyst target of A$0.50 (TipRanks, late 2025) predates the July 2026 setback and should be treated as stale.
Bull case
-
The platform is validated by a strong partner. Promega's continued orders and a customer base growing from about 60 to 90 in one year suggest EXO-NET has real scientific utility. That underpins credibility for EXO-OC and the CAR-exosome programs, which are built on the same technology.
-
The EXO-OC failure was about the samples, not the test. Single-site data (100% Stage I/II sensitivity at 99.6% specificity) and the optimised algorithm (92.3% and 92.5% at 98% specificity) remain strong. The failure was traced to degraded biobank samples from one provider that supplied 69% of cancer cases. A controlled-protocol study could restore the thesis, and the high-risk LDT entry point is commercially reachable.
-
The valuation reflects cash, not the pipeline. At about A$15.6m EV, the market ascribes little value to a therapeutic platform with in vivo TNBC efficacy, three CAR-exosome indications, 29 granted patents and the neuCA15-3 asset. A partnering deal for any one asset could re-rate the stock.
Bear case
-
Funding and dilution. Operating burn of about A$6.4m a year against A$9.35m in cash points to a raise around 2027. At current prices, a A$10m raise could dilute holders by roughly 40% or more. Weak SPP take-up in 2025 suggests limited retail appetite.
-
The evidence gap is widening. EXO-OC still lacks independent validation more than a year after its headline data. Ovarian screening has a history of disappointing trials, and the move to high-risk populations narrows the near-term market. LDT partners will require robust, multi-site validation that has yet to be generated.
-
The commercial base is eroding. Product revenue fell 21% in FY2026. hTERT is in structural decline and EXO-NET revenue is volatile and still under A$0.3m after nearly four years on the market. Annual amortisation of about A$0.95m on legacy intangibles also creates impairment risk.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Design and launch of the new EXO-OC validation study (sample source, size, partner) | FY2027 H1 to H2 | Determines credibility and timeline to LDT |
| Announcement of a US CLIA laboratory partner | FY2027 | Converts EXO-OC into a commercial pathway |
| CAR-exosome CDMO selection and GMP readiness; dual-action CAR-exosome data | FY2027 | Gating items for the 2028 first-in-human target |
| Quarterly Appendix 4C reports (Oct 2026, Jan 2027, Apr 2027) | Quarterly | Cash burn and runway |
| Receipt of the FY2026 R&D tax refund (A$1.78m) | Coming months | Liquidity |
| 2026 AGM (approximately November 2026) | Nov 2026 | Board votes, remuneration, any capital-management resolutions |
| EXO-NET order flow from Promega; EXO-NET/RNA product launch | Ongoing | Evidence of a recurring revenue base |
| neuCA15-3 automated platform transfer and partnering | FY2027 | Optionality on a secondary asset |
| Capital raising or strategic transaction (possibly involving Tian An Medicare) | 2027 likely | Dilution and control dynamics |
Concluding analyst verdict
INOVIQ, formerly BARD1 Life Sciences, is a scientifically credible but commercially early-stage exosome platform company. Its investment case has become meaningfully riskier over the past six months. Since the 2020 Sienna merger, the company has executed reasonably well at the technology level. It built the EXO-NET isolation platform, secured Promega as global distributor, accumulated 29 granted patents, generated peer-reviewed validation for neuCA15-3 and CAR-exosome manufacturing, and produced in vivo efficacy for a cell-free CAR therapy in TNBC. It has also maintained a disciplined cost base by biotech standards, with annual losses of A$6.5m to A$7.5m and a debt-free balance sheet.
The core problem is that none of these achievements has yet turned into meaningful revenue or a validated clinical product. Product revenue of A$0.43m in FY2026 fell 21%. The flagship EXO-OC program, which the October 2025 A$10.2m raise was specifically designed to accelerate, suffered a validation failure in July 2026. The root cause appears to be external sample quality rather than test performance, but the practical result is roughly a year's delay, about A$0.85m of sunk cost and a halved share price. With A$9.35m of cash at June 2026 and an annual operating burn above A$6m, the company is likely to need fresh capital in 2027, probably at prices well below the 2025 placement.
The current valuation of about A$25m market capitalisation and about A$15m EV already discounts much of this. The stock trades at a modest premium to book and roughly twice tangible assets, so any partnering success, whether a US LDT laboratory for EXO-OC or a therapeutic licensing deal, would be disproportionately value-accretive. The presence of a 10% strategic holder, Tian An Medicare, and a chairman linked to that holder adds both financing optionality and possible corporate-activity angles.
Verdict: a high-risk, binary-catalyst speculative holding. The next 12 months will turn on two tests: whether management can design and fund an independent EXO-OC validation that satisfies US laboratory partners, and whether CAR-exosome manufacturing readiness attracts pharma interest. Until either is delivered, dilution risk dominates. Investors should key positioning to the quarterly cash reports and to any partner announcement, rather than to the headline sensitivity figures.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background and education | Other current listed boards | Committees |
|---|---|---|---|---|---|
Peter Gunzburg | Non-Executive Chairman | Director 20 Oct 2025; Chairman 18 Dec 2025 | 40+ years as public company director, stockbroker and investor. BCom (UWA). Chairman of BARD1 2016 to 2020. Former director of Australian Stock Exchange Ltd, Eyres Reed and CIBC World Markets Australia. | Chairman, Metals X (ASX: MLX); NED, First Tin Plc (LSE: 1SN) | Not specified in excerpts |
Dr Geoffrey Cumming | Non-Executive Director | 28 Jul 2020 | BSc (Hons), BAppSc, PhD, MBA, MAICD. Former MD of Roche Diagnostic Systems (Oceania), CEO of Biosceptre International, MD/CEO of Anteo Diagnostics. Former Chairman of Sienna Cancer Diagnostics. | NED, Anteo Diagnostics (ASX: ADO) | Chair, Remuneration; member, Audit & Risk |
Robert (Max) Johnston | Non-Executive Director | 17 Jun 2019 | 11 years as President and CEO of Johnson & Johnson Pacific; earlier roles at Diageo and Unilever. Former chair or director of Probiotec, AusCann, PolyNovo, Medical Developments International, Enero and Tissue Repair. | NED, Neurotech International (ASX: NTI) | Member, Remuneration and Audit & Risk |
Philip Powell | Non-Executive Director | 17 Jun 2019 | BComm (Hons), ACA, MAICD. Chartered accountant and investment banker; 10 years at OAMPS, 10 years at Arthur Andersen. Former NED of RMA Global, PolyNovo and Medical Developments International. | None currently | Chair, Audit & Risk |
Mary Harney | Non-Executive Director | 1 Oct 2024 | IDP-C INSEAD, BSc, BA (Fine Arts), MAICD, FIML. Director of Mary Harney Advisory. Former Chair of Race Oncology and Microbio. | Chair, Oncology One Pty Ltd (private) | Not specified in excerpts |
David Williams (former) | Non-Executive Chairman | 29 Nov 2023 to 18 Dec 2025 (resigned) | Investment banker and MD of Kidder Williams; Chairman of RMA Global; former Chairman of PolyNovo. | — | — |
Executive Leadership Team
| Name | Title | Appointed | Background / education |
|---|---|---|---|
Dr Leearne Hinch | Chief Executive Officer | 7 Nov 2016 | BSc, BVMS, MBA (Distinction). Founder of the Ingeneus Solutions consultancy. Roles at HealthLinx, OBJ, Holista Colltech, Chemeq, Virbac and Mars Petcare UK. Led the Sienna acquisition and the pivot to exosomes. |
Mark Edwards | CFO and Company Secretary | 2 Nov 2022 | BAcc, CA. Eight years as CFO and Company Secretary at Medical Developments International; Head of Finance at Cogstate; 14 years at EY. |
Dr Rebecca Lim | Chief Scientific Officer | 12 Jan 2026 | BSc (Hons), PhD. Former Director of Strategic Alliances at CTMC (an MD Anderson and National Resilience CDMO joint venture); SVP Scientific Affairs at Prescient Therapeutics; A/Prof at Monash University. |
Prof Gregory Rice | Founding Scientist and Advisor | 20 Sep 2021 | PhD, BSc (Hons) (UWA), MHA, Grad Dip Mgt. More than 280 publications. Former Director of the UQ Centre for Clinical Diagnostics; co-founder and CSO of HealthLinx; CEO of Pregnostica SpA. |
Emma Ball | Chief Commercial Officer | — | Listed by Statbase aggregator; not shown as KMP in AR FY2026 |
“—” = not publicly disclosed.
Directors' Remuneration
| KMP | Year | Salary / fees | Bonus | Super | Long-term | Share-based payments | Total |
|---|---|---|---|---|---|---|---|
P Gunzburg (Chair) | FY2026 | 57,219 | 0 | 6,866 | 0 | 0 | 64,085 |
D Williams (former Chair) | FY2026 | 45,045 | 0 | 5,405 | 0 | -426,460 | -376,010 |
D Williams (former Chair) | FY2025 | 90,090 | 0 | 10,360 | 0 | 634,922 | 735,372 |
G Cumming (NED) | FY2026 | 60,000 | 0 | 7,200 | 0 | 22,905 | 90,105 |
P Powell (NED) | FY2026 | 60,000 | 0 | 7,200 | 0 | 22,905 | 90,105 |
M Johnston (NED) | FY2026 | 60,000 | 0 | 7,200 | 0 | 22,905 | 90,105 |
M Harney (NED) | FY2026 | 60,000 | 0 | 7,200 | 0 | 22,905 | 90,105 |
L Hinch (CEO) | FY2026 | 449,946 | 0 | 30,000 | 10,995 | 22,907 | 513,848 |
L Hinch (CEO) | FY2025 | 430,193 | 90,000 | 29,932 | 10,372 | 60,839 | 621,336 |
M Edwards (CFO) | FY2026 | 294,639 | 0 | 30,000 | 6,791 | 11,774 | 343,204 |
G Rice (Founding Scientist) | FY2026 | 224,321 | 0 | 26,062 | 5,525 | 11,781 | 267,689 |
R Lim (CSO, part year) | FY2026 | 130,389 | 0 | 14,683 | 238 | 9,319 | 154,629 |
Total KMP | FY2026 | 1,441,559 | 0 | 141,816 | 23,549 | -279,059 | 1,327,865 |
Total KMP | FY2025 | 1,234,914 | 147,303 | 124,259 | 21,312 | 789,517 | 2,317,305 |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Tian An Medicare Limited (HKEX: 0383) | 14,285,714 | 10.15 |
Merchant Funds Management Pty Ltd | 9,183,919 | 6.52 |
Major Shareholders by Rank
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | BNP Paribas Noms Pty Ltd (custodian; likely includes the Tian An stake) | 14,737,871 | 10.47 |
| 2 | The Trust Company Australia Ltd (MOF A/C) | 7,201,286 | 5.12 |
| 3 | Dr Irmgard Irminger-Finger (BARD1 founder) | 2,860,000 | 2.03 |
| 4 | Lawn Views Pty Ltd (Angela Williams Family A/C) | 2,676,924 | 1.90 |
| 5 | DS Shares Pty Ltd | 1,700,000 | 1.21 |
| 6 | Lesamourai Pty Ltd | 1,500,000 | 1.07 |
| 7 | Supergun Pty Ltd (Bricklanding Super Fund) | 1,321,000 | 0.94 |
| 8 | Citicorp Nominees Pty Ltd | 1,291,981 | 0.92 |
| 9 | Trovex Pty Ltd | 1,250,143 | 0.89 |
| 10 | Palmers Plumbing & Hardware Pty Ltd | 1,250,000 | 0.89 |
Directors' Shareholdings
| Director | Ordinary shares | ESS options | Listed options |
|---|---|---|---|
Peter Gunzburg | 3,693,000 | 0 | 315,000 |
Max Johnston | 990,024 | 250,000 | 100,000 |
Philip Powell | 670,344 | 250,000 | 30,000 |
Geoffrey Cumming | 237,414 | 250,000 | 30,000 |
Mary Harney | 60,000 | 250,000 | 0 |
Competitive Landscape
Key Competitors
| Competitor | Relevant offering | Scale (indicative) | Positioning versus INOVIQ |
|---|---|---|---|
Thermo Fisher Scientific (US) | Total Exosome Isolation reagents, Invitrogen EV kits | Group revenue about US$43bn (CY2024) | Huge channel and brand; reagent-based precipitation |
Qiagen (NL/DE) | exoRNeasy / exoEasy kits | Group revenue about US$2.0bn (CY2024) | Strong in RNA workflows, which competes with the EXO-NET/RNA combination product |
Bio-Techne (US) | Exosome Diagnostics (ExoDx) platform and reagents | Group revenue about US$1.2bn (FY Jun 2025) | Integrated EV diagnostics and reagents |
Izon Science (NZ, private) | qEV size-exclusion columns | — | A de facto standard in EV research labs |
System Biosciences (US, private) | ExoQuick precipitation | — | Long-established low-cost reagent |
Miltenyi Biotec (DE, private) | MACSPlex / immunocapture EV kits | — | Immunoaffinity capture |
“—” = not publicly disclosed.
Key Competitors — Roche Diagnostics
| Competitor | Relevant offering | Positioning |
|---|---|---|
Roche Diagnostics | Elecsys CA125 and HE4 (ROMA) | Entrenched incumbent biomarkers; EXO-OC itself incorporates CA125 |
Fujirebio | Lumipulse CA125, HE4, ROMA | Incumbent IVD assays |
Aspira Women's Health (US) | Ova1, Overa, OvaWatch (adnexal mass risk assessment) | The closest US commercial ovarian blood-test comparator; a small-cap with persistent losses |
GRAIL (US) | Galleri multi-cancer early detection | Includes ovarian signals; well funded; LDT model |
Exact Sciences (US) | Multi-cancer early detection (Cancerguard) | Large commercial footprint |
Mainstream CA15-3 assay suppliers (Roche, Abbott, Siemens Healthineers) | CA15-3 monitoring assays | Incumbents that neuCA15-3 seeks to improve on |
Key Competitors — Pacific Edge
| Competitor | Relevant offering | Positioning |
|---|---|---|
Pacific Edge (NZ, NZX: PEB) | Cxbladder urine tests | Molecular urine test; the company has faced US reimbursement challenges |
Abbott | UroVysion FISH | Incumbent cytology adjunct |
Newer molecular urine tests | Various | Cited by management as new competition for hTERT |
Key Competitors — Evox Therapeutics
| Competitor | Status | Positioning |
|---|---|---|
Evox Therapeutics (UK, private) | Engineered exosome drug delivery | Well-funded EV therapeutics peer |
Capricor Therapeutics (US) | Exosome platform alongside a cell therapy lead | Listed EV-adjacent peer |
Codiak BioSciences (US) | Engineered exosomes | Filed for bankruptcy in 2023; a cautionary precedent for EV therapeutics funding |
CAR-NK and CAR-T developers (e.g., Nkarta, Fate Therapeutics) | Cell-based therapies | INOVIQ positions CAR-exosomes as a cell-free, off-the-shelf alternative |
Peer Comparison FY2026
| Metric | INOVIQ (FY Jun 2026) | Bio-Techne (FY Jun 2025) | Qiagen (CY2024) | Aspira Women's Health (CY2024) |
|---|---|---|---|---|
Revenue | A$0.43m | about US$1.2bn | about US$2.0bn | about US$9m (indicative) |
Revenue growth | -21.1% | low single digit | low single digit | — |
Gross margin | 82.2% | about 65 to 70% | about 65% (adjusted) | — |
Operating margin | about -1,500% (derived) | positive | positive | strongly negative |
R&D intensity | 1,081% of revenue | about 8 to 10% | about 9 to 10% | high |



